What should be done next for a patient with moderate COPD who is already on Breztri (beclomethasone/formoterol/glycopyrronium) and a salbutamol (albuterol) rescue inhaler that is being depleted too quickly, given a normal lung CT and moderate disease on pulmonary function testing?

Reassess Inhaler Technique and Optimize Rescue Medication Use

This patient's excessive rescue inhaler use while on maximal triple therapy (Breztri) indicates either poor disease control, incorrect inhaler technique, or inappropriate rescue medication reliance—you need to first verify proper inhaler technique for both devices, then assess whether the patient is truly experiencing increased symptoms or simply overusing salbutamol out of habit or anxiety.

Immediate Assessment Steps

1. Verify Inhaler Technique

• Directly observe the patient using both the Breztri Aerosphere inhaler and salbutamol MDI
• Common errors with Breztri include inadequate breath-hold (should be 10 seconds), not shaking the device, or poor coordination
• Incorrect technique can result in inadequate drug delivery, mimicking treatment failure 1

2. Quantify Rescue Inhaler Use

• Determine exactly how often the patient uses salbutamol (more than 2-4 puffs daily suggests poor control)
• Assess when rescue medication is needed: at rest, with activity, or prophylactically before exertion
• Rule out that the patient is using salbutamol as maintenance therapy rather than true rescue medication

3. Confirm Medication Adherence

• Verify the patient takes Breztri exactly as prescribed: 2 inhalations twice daily (morning and evening) 1
• Patients sometimes reduce controller medication when feeling better, leading to symptom recurrence

Clinical Evaluation Required

Assess for Acute Exacerbation

Determine if increased rescue use represents an acute exacerbation requiring immediate intervention 2:

• Increased breathlessness beyond usual day-to-day variation
• Increased sputum volume
• Development of purulent sputum
• New or worsening wheeze

If exacerbation present: Add oral corticosteroids (30 mg prednisone daily for 7 days) and antibiotics if two or more cardinal symptoms present 2, 3

Rule Out Alternative Diagnoses

Given the normal CT scan, consider:

• Cardiac dysfunction (left ventricular failure can mimic COPD symptoms)
• Pulmonary embolism (especially if acute worsening)
• Anxiety/hyperventilation (can drive excessive rescue inhaler use)
• Gastroesophageal reflux (can worsen respiratory symptoms)

Management Algorithm

If Technique and Adherence Are Adequate:

Step 1: Consider Adding Long-Term Macrolide Therapy

• For patients with moderate COPD who continue to have symptoms or exacerbations despite triple therapy, add azithromycin 250 mg three times weekly 4
• This recommendation is supported by moderate certainty evidence showing reduced exacerbation rates
• Important caveats: Screen for baseline QTc prolongation, obtain baseline audiometry, counsel about antimicrobial resistance risk 4

Step 2: Consider Pulmonary Rehabilitation

• Refer to pulmonary rehabilitation program if not already enrolled
• Should be initiated within 3 weeks of any exacerbation 3
• Improves exercise tolerance, dyspnea, and quality of life independent of pharmacotherapy

Step 3: Reassess Eosinophil Count

• If blood eosinophils ≥300 cells/μL, the ICS component of Breztri is particularly beneficial
• If eosinophils <100 cells/μL, consider whether ICS withdrawal might be appropriate (though not recommended in this scenario given ongoing symptoms) 4

If Technique or Adherence Issues Identified:

Correct the technique deficits immediately and reassess in 2-4 weeks before escalating therapy. The evidence shows that proper inhaler technique is critical for triple therapy effectiveness 5, 6, 7.

Common Pitfalls to Avoid

1. Do not add nebulized bronchodilators without formal assessment: While older guidelines 8 suggest nebulizer therapy for severe COPD, this requires specialist evaluation with peak flow monitoring and documented >15% improvement over baseline before prescribing long-term nebulized therapy

2. Do not step down from triple therapy: The evidence shows that withdrawing ICS from triple therapy in symptomatic patients with moderate COPD increases exacerbation risk, particularly with eosinophils ≥300 cells/μL 4

3. Do not prescribe additional LABAs or LAMAs: Breztri already contains formoterol (LABA) and glycopyrronium (LAMA). Adding ipratropium or additional long-acting bronchodilators is contraindicated and increases adverse event risk 1

4. Recognize that "normal" CT does not exclude significant COPD: Moderate COPD on PFTs with normal CT suggests predominantly small airways disease, which may respond particularly well to extrafine particle formulations like Breztri 6, 7, 9

Expected Outcomes

With proper technique and adherence, patients on Breztri should experience:

• Reduced rescue medication use to <2-4 puffs daily
• Improved CAT scores (typically 3-6 point reduction) 5, 6
• Reduced exacerbation frequency 10, 11
• Improved FEV1 (typically 60-140 mL improvement) 5, 6

If symptoms persist despite verified proper technique and adherence after 4-6 weeks, specialist respiratory consultation is warranted to consider additional interventions such as macrolide therapy, roflumilast (if chronic bronchitic phenotype), or evaluation for comorbidities.